FI970588L - Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä - Google Patents

Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä Download PDF

Info

Publication number
FI970588L
FI970588L FI970588A FI970588A FI970588L FI 970588 L FI970588 L FI 970588L FI 970588 A FI970588 A FI 970588A FI 970588 A FI970588 A FI 970588A FI 970588 L FI970588 L FI 970588L
Authority
FI
Finland
Prior art keywords
methods
inflammatory diseases
treating sepsis
oxypurine nucleosides
oxypurine
Prior art date
Application number
FI970588A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970588A7 (fi
FI970588A0 (fi
Inventor
Borstel Reid W Von
Michael K Bamat
Bradley M Hiltbrand
James C Butler
Shyam Shirali
Original Assignee
Pro Neuron Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc
Publication of FI970588A0 publication Critical patent/FI970588A0/fi
Publication of FI970588A7 publication Critical patent/FI970588A7/fi
Publication of FI970588L publication Critical patent/FI970588L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
FI970588A 1994-08-12 1995-08-08 Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä FI970588L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28921494A 1994-08-12 1994-08-12
PCT/US1995/010078 WO1996004923A1 (en) 1994-08-12 1995-08-08 Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides

Publications (3)

Publication Number Publication Date
FI970588A0 FI970588A0 (fi) 1997-02-12
FI970588A7 FI970588A7 (fi) 1997-04-11
FI970588L true FI970588L (fi) 1997-04-11

Family

ID=23110539

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970588A FI970588L (fi) 1994-08-12 1995-08-08 Menetelmät verenmyrkytyksen tai tulehdussairauksien hoitamiseksi oksipuriininukleosideillä

Country Status (12)

Country Link
US (1) US20040235782A1 (no)
EP (2) EP1157698A3 (no)
JP (2) JPH10507441A (no)
KR (1) KR100290129B1 (no)
AU (1) AU712835B2 (no)
CA (1) CA2197205A1 (no)
FI (1) FI970588L (no)
IL (1) IL114887A0 (no)
NO (3) NO970631L (no)
RU (1) RU2203669C2 (no)
WO (1) WO1996004923A1 (no)
ZA (1) ZA956679B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DK2223922T3 (en) * 2000-04-25 2016-06-06 Icos Corp Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
CA2452909A1 (en) * 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
AU2003293310B2 (en) 2002-09-30 2010-04-01 Bayer Intellectual Property Gmbh Fused azole-pyrimidine derivatives
US6997018B2 (en) 2003-06-02 2006-02-14 Ferro Corporation Method of micro and nano texturing glass
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP5718639B2 (ja) 2007-08-16 2015-05-13 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 電離放射線誘発の損傷から哺乳類細胞を保護する方法
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20160091440A (ko) 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
BR112012027740B1 (pt) * 2010-04-29 2021-02-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. composições contendo nucleosídeos de purina e pirimidina, peptídeos e maganês e seus usos
EA025407B1 (ru) 2012-03-05 2016-12-30 Джилид Калистога Ллс Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
AR123337A1 (es) * 2020-08-24 2022-11-23 Adama Makhteshim Ltd Compuestos y composiciones plaguicidas, métodos de uso y procesos de preparación de las mismas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529205A (en) * 1983-10-20 1985-07-16 Bowker Dennis E Winery game board
WO1992013561A1 (en) * 1991-02-08 1992-08-20 Pro-Neuron, Inc. Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
US5320846A (en) * 1991-04-17 1994-06-14 New England Deaconess Hospital Corp. Method and composition for testing patients with metabolic depleting diseases

Also Published As

Publication number Publication date
JPH10507441A (ja) 1998-07-21
WO1996004923A1 (en) 1996-02-22
US20040235782A1 (en) 2004-11-25
RU2203669C2 (ru) 2003-05-10
KR970704457A (ko) 1997-09-06
NO20016068D0 (no) 2001-12-12
NO20016068L (no) 1997-04-11
ZA956679B (en) 1997-02-10
EP1157698A2 (en) 2001-11-28
JP2009221221A (ja) 2009-10-01
AU3278495A (en) 1996-03-07
EP0771204A1 (en) 1997-05-07
NO317199B1 (no) 2004-09-13
EP1157698A3 (en) 2002-05-02
KR100290129B1 (ko) 2001-05-15
NO20041007L (no) 2004-03-10
EP0771204A4 (en) 1999-10-20
FI970588A7 (fi) 1997-04-11
NO970631L (no) 1997-04-11
IL114887A0 (en) 1995-12-08
CA2197205A1 (en) 1996-02-22
AU712835B2 (en) 1999-11-18
NO970631D0 (no) 1997-02-11
FI970588A0 (fi) 1997-02-12

Similar Documents

Publication Publication Date Title
DE69724355D1 (de) Erweiterte symmetrische Multiprozessorarchitektur
FI943625L (fi) Menetelmiä tulehduksellisten ihotautien hoitamiseksi
FI99070B (fi) Teline
BR9607530A (pt) Cache de configuração rápida
FI961430L (fi) Prosessi I
KR970704457A (ko) 옥시퓨린 누클레오시드로 패혈증 또는 염증성 질병을 치료하는 방법(methods for treating sepsis or inflammatory diseasos with oxypurine nucleosides)
DE69613286D1 (de) Elektroplattierungsverfahren
DE69512005D1 (de) Schusswaffe
DE69700667D1 (de) Elektroplattierungsverfahren
DK0770198T3 (da) Forbrændingsfremgangsmåde
DE69400308D1 (de) Verbrennungsverfahren
DE69414324D1 (de) Elektrobeschichtungsverfahren
DE69515305D1 (de) Persönliches feuerwaffensystem
DE69728086D1 (de) Erweiterte symmetrische Multiprozessorarchitektur
FI954245A7 (fi) Koostumuksia ja menetelmiä immunovälitteisten tulehduksellisten häiriö iden hoitamiseksi
DE69507032D1 (de) Chlorhydrin-verfahren
DE69634464D1 (de) Cachespeicher
FI964468A0 (fi) Adenosiinijohdannaisia
HK1004466A (en) Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides
FI962750A7 (fi) Menetelmä neurogeenisen tulehduksen hoitamiseksi
KR970029089U (ko) 자동차용 몰딩
KR960003946U (ko) 세면구 보관대
SE9301925D0 (sv) Nivaaroer foer badkar
IT235128Y1 (it) Cassa continua per interni
BR7501874U (pt) Disposição introduzida em fueiros telescópio

Legal Events

Date Code Title Description
MA Patent expired